Market Overview

UPDATE: Stifel Nicolaus Cuts PT to $26 on Ariad Pharmaceuticals on Tempered Iclusig Outlook

Related ARIA
ARIAD Announces Recommendation For Iclusig By The Pharmacovigilance Risk Assessment Committee Of The European Medicines Agency
Markets Mixed; Constellation Brands Posts Downbeat Profit
Wayfair Rises, Westport Innovations Cuts Forecast (Fox Business)

Stifel Nicolaus maintained Ariad Pharmaceuticals (NASDAQ: ARIA) with a Buy rating and lowered the price target from $27.00 to $26.00.

Stifel Nicolaus noted, "We surveyed 34 hematology/oncology specialists in February. Results continue to suggest best-in-class potential for Iclusig in third-line and later-line therapy but greater uncertainty than before regarding Iclusig's front-line potential on the heels of black box warnings for thrombosis and hepatotoxicity. We decrease our target price to $26 from $27 as we decrease our Iclusig sales and out-year EPS estimates."

Ariad Pharmaceuticals closed at $20.08 on Wednesday.

Latest Ratings for ARIA

DateFirmActionFromTo
Aug 2014CitigroupMaintainsSell
Aug 2014JMP SecuritiesMaintainsMarket Outperform
Jun 2014UBSMaintainsNeutral

View More Analyst Ratings for ARIA
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Analyst Ratings

 

Related Articles (ARIA)

Around the Web, We're Loving...

Get Benzinga's Newsletters